PDCD1 and neoplasm: In order to understand how antibody isotype differences may impact the anti-tumor efficacy of anti-TIGIT antibodies we evaluated the antibodies as single agents and in combination with the anti-mouse PD-1 antibody, clone DX400 in mIgG1* isotype (hereafter, anti-PD-1), in multiple mouse syngeneic tumor models.